Wegovy: Complete Guide to Semaglutide 2.4 mg for Weight Loss

What Is Wegovy and How Does It Work?

Wegovy is a subcutaneous injection of semaglutide at the 2.4 mg dose, given once per week. Semaglutide mimics the naturally occurring hormone glucagon-like peptide-1 (GLP-1), binding to GLP-1 receptors in the pancreas, gastrointestinal tract, and brain. The result is a coordinated reduction in appetite, slower gastric emptying, and improved insulin secretion in a glucose-dependent fashion. [1]

GLP-1 receptors in the hypothalamus suppress hunger signals directly. Reduced gastric emptying prolongs feelings of fullness after meals. Together, these two mechanisms typically lower daily caloric intake by 300 to 500 calories in clinical trials, without requiring conscious dietary restriction to achieve the effect. The semaglutide molecule in Wegovy is chemically identical to Ozempic, but the approved dose is higher: 2.4 mg weekly versus a maximum of 2 mg weekly for Ozempic. That dose difference explains most of the efficacy gap between the two brand names. [1][2]

Semaglutide was originally developed as a weekly alternative to daily liraglutide (Victoza, Saxenda) for type 2 diabetes. Researchers noticed substantial weight loss in diabetic trial participants and launched the dedicated STEP (Semaglutide Treatment Effect in People with Obesity) program to evaluate the 2.4 mg dose specifically for obesity. [3]

Wegovy Dosing Schedule and Titration

The FDA-approved titration schedule for Wegovy runs 16 weeks before reaching the full 2.4 mg maintenance dose. Slow titration reduces the severity of nausea and gastrointestinal side effects. [1]

The published schedule from the Wegovy prescribing information is:

• Weeks 1 through 4: 0.25 mg once weekly
• Weeks 5 through 8: 0.5 mg once weekly
• Weeks 9 through 12: 1.0 mg once weekly
• Weeks 13 through 16: 1.7 mg once weekly
• Week 17 onward: 2.4 mg once weekly (maintenance)

If a patient cannot tolerate 2.4 mg, the prescribing information allows a temporary reduction to 1.7 mg for four weeks before reattempting the full dose. Patients who still cannot tolerate 1.7 mg should discontinue the medication. [1] Injections go into the abdomen, thigh, or upper arm, and the injection day can be changed by up to 72 hours without clinical consequence.

Clinical Trial Results: What the STEP Program Found

The STEP program is a series of Phase 3 randomized controlled trials that established Wegovy's efficacy and safety profile across several patient populations.

STEP-1 (N=1,961 to 68 weeks): Adults with BMI ≥30, or BMI ≥27 with at least one comorbidity, randomized to semaglutide 2.4 mg or placebo alongside lifestyle intervention. Participants on semaglutide lost a mean 14.9% of body weight versus 2.4% on placebo (difference: 12.4 percentage points, P<0.001). 86.4% of semaglutide participants achieved at least 5% weight loss. [3]

STEP-2 (N=1,210 to 68 weeks): Adults with both overweight/obesity and type 2 diabetes. Mean weight loss was 9.6% with semaglutide 2.4 mg versus 3.4% with placebo. Weight loss is attenuated in people with type 2 diabetes compared with those without, a pattern seen across the GLP-1 class. [4]

STEP-3 (N=611 to 68 weeks): Semaglutide 2.4 mg combined with intensive behavioral therapy (IBT) involving 30 counseling sessions. The combination produced 16.0% mean weight loss versus 5.7% with placebo plus IBT, a difference of 10.3 percentage points (P<0.001). [5]

STEP-5 (N=304 to 104 weeks): The only two-year randomized data for semaglutide 2.4 mg. Participants maintained a mean 15.2% weight loss through week 104, compared with 2.6% on placebo, demonstrating durable efficacy. [6]

STEP-8 (N=338 to 68 weeks): A direct head-to-head comparison between semaglutide 2.4 mg (weekly) and liraglutide 3.0 mg (daily, the Saxenda dose). Semaglutide produced 15.8% weight loss versus 6.4% with liraglutide, nearly 2.5 times greater weight loss from the same drug class. [7]

The pattern across the STEP program is consistent: semaglutide 2.4 mg produces roughly 15% mean weight loss in people without diabetes over 68 weeks, which is approximately double what older agents like liraglutide achieve.

Wegovy vs. Ozempic: Same Drug, Different Doses and Approvals

Ozempic and Wegovy both contain semaglutide. The distinction comes entirely from dose and FDA indication.

Ozempic is approved for type 2 diabetes management at doses of 0.5 mg, 1 mg, or 2 mg weekly. It carries a secondary cardiovascular risk-reduction indication. Wegovy is approved specifically for chronic weight management at 2.4 mg weekly. Neither drug is technically approved for the other's primary indication, though prescribers sometimes use Ozempic off-label for weight loss when Wegovy is unavailable or cost-prohibitive. [1][2]

The STEP-2 trial used both the 1 mg and 2.4 mg doses in patients with type 2 diabetes. The 2.4 mg dose produced meaningfully greater A1C and weight reductions than the 1 mg dose, confirming that dose matters. At 1 mg weekly, semaglutide produces roughly 6% weight loss; at 2.4 mg weekly, it produces roughly 15%. Patients using Ozempic for weight loss are, by definition, using a lower dose and should expect less weight reduction than published Wegovy data show. [4]

Cost differences also matter in practice. Ozempic's list price is approximately $935 per month; Wegovy lists at approximately $1,350 per month. Insurance coverage varies substantially: most commercial plans with obesity benefits cover Wegovy, while Ozempic coverage is tied to a documented diabetes diagnosis.

Wegovy vs. Zepbound: GLP-1 Alone vs. Dual GLP-1/GIP Agonism

Zepbound (tirzepatide 2.5 to 15 mg weekly) adds agonism at the glucose-dependent insulinotropic polypeptide (GIP) receptor alongside GLP-1 receptor activation. Whether dual agonism explains tirzepatide's additional weight-loss efficacy over semaglutide is still being studied, but the clinical data show a consistent separation. [8]

In SURMOUNT-1 (N=2,539 to 72 weeks), tirzepatide 15 mg produced a mean 20.9% weight loss versus 3.1% with placebo. The 10 mg dose produced 19.5% weight loss. [8] No head-to-head trial of tirzepatide 15 mg versus semaglutide 2.4 mg has been published as of mid-2025, but indirect comparisons using the STEP and SURMOUNT programs consistently favor tirzepatide by approximately 5 to 7 percentage points of body weight.

SURMOUNT-4 (N=670) addressed what happens when tirzepatide is stopped. After 36 weeks of open-label tirzepatide followed by 52 weeks of randomized continuation or placebo, those who switched to placebo regained a mean 14.8% body weight versus 5.5% additional loss in those who continued. [9] The same pattern holds for semaglutide: STEP-5 showed weight regain begins within weeks of discontinuation. Both drugs appear to require ongoing use to maintain weight loss.

For patients who cannot tolerate the higher gastrointestinal burden sometimes reported with tirzepatide escalation, semaglutide 2.4 mg remains a well-established alternative with five years of post-approval safety data.

Wegovy vs. Saxenda: Weekly vs. Daily Injections

Saxenda (liraglutide 3.0 mg) was the first GLP-1 receptor agonist FDA-approved specifically for obesity, receiving that designation in December 2014. Wegovy followed in June 2021. Both drugs come from Novo Nordisk and work through GLP-1 receptor agonism, but liraglutide's shorter half-life (approximately 13 hours) requires daily injections versus Wegovy's once-weekly schedule. [7]

STEP-8 settled the efficacy question directly. Semaglutide 2.4 mg weekly beat liraglutide 3.0 mg daily with 15.8% versus 6.4% mean weight loss at 68 weeks. More participants on semaglutide achieved 5% weight loss (85.1% vs. 55.4%) and 10% weight loss (69.9% vs. 28.5%). [7] Adverse event profiles were broadly similar between the two drugs. Given the large efficacy advantage and the weekly versus daily injection burden, clinical guidelines generally favor semaglutide over liraglutide when both are available and covered.

Saxenda retains a role for patients who cannot access or afford Wegovy, and for adolescents aged 12 to 17 years where Saxenda has an FDA approval that predates Wegovy's own adolescent indication.

Cardiovascular Benefits: The SELECT Trial

Weight loss alone does not fully explain Wegovy's cardiovascular data. The SELECT trial (N=17,604) enrolled adults with established cardiovascular disease who were overweight or obese but did not have diabetes. Participants received semaglutide 2.4 mg or placebo for a mean follow-up of 39.8 months. [10]

The primary endpoint, a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke (MACE-3), occurred in 6.5% of the semaglutide group versus 8.0% of the placebo group, representing a 20% relative risk reduction (hazard ratio 0.80 to 95% CI 0.72 to 0.90, P<0.001). [10]

The Wegovy prescribing information, updated in 2024, now includes a cardiovascular risk-reduction indication for adults with established cardiovascular disease and BMI ≥27. [1] This makes Wegovy the first obesity pharmacotherapy with an FDA-approved cardiovascular outcomes label.

The ACC/AHA guidelines on obesity and cardiovascular disease have incorporated these findings, noting that GLP-1 receptor agonist therapy should be considered in patients with obesity and atherosclerotic cardiovascular disease regardless of glycemic status. [10]

Who Qualifies for Wegovy?

The FDA-approved indications, per the current prescribing information, include adults with: [1]

• Initial BMI ≥30 (obesity), or
• Initial BMI ≥27 (overweight) with at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.

Wegovy also carries approval for adolescents aged 12 and older with initial BMI at or above the 95th percentile for age and sex.

The AACE/ACE obesity clinical practice guidelines recommend anti-obesity pharmacotherapy as an adjunct to lifestyle intervention when behavioral approaches alone produce insufficient weight loss, particularly in patients with a BMI ≥27 and at least one comorbidity. [11] Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2) are contraindicated for Wegovy. [1]

Side Effects and Safety Profile

Gastrointestinal adverse events are the most common reason for dose reduction or discontinuation. In STEP-1, nausea occurred in 44% of semaglutide participants versus 16% on placebo; diarrhea in 30% versus 16%; vomiting in 24% versus 6%; and constipation in 24% versus 11%. [3] Most events were mild to moderate and occurred during dose escalation, with the majority resolving within 4 to 8 weeks of reaching a stable dose.

Serious but less common adverse events include:

• Acute pancreatitis (reported in 0.3% of semaglutide participants in STEP-1 versus 0.1% on placebo) [3]
• Gallbladder disease, including cholelithiasis, occurring at higher rates with rapid weight loss on any pharmacotherapy
• Heart rate increase averaging 1 to 4 beats per minute, without documented clinical sequelae in trials
• Rare injection-site reactions

Wegovy does not cause hypoglycemia in people without diabetes. The glucose-dependent mechanism of GLP-1 receptor agonists shuts off insulin stimulation when blood glucose falls to normal levels, distinguishing this class from sulfonylureas or insulin. [1]

Muscle mass loss accompanies weight loss with Wegovy, as with all significant caloric deficit strategies. Resistance exercise during treatment is routinely recommended by obesity medicine specialists to preserve lean mass, though Wegovy's labeling does not mandate a specific exercise protocol.

What Happens When You Stop Wegovy?

Weight regain after stopping semaglutide is well-documented. In a randomized withdrawal study following STEP-1, participants who discontinued semaglutide after 68 weeks and were followed for an additional 52 weeks regained a mean two-thirds of their prior weight loss. By week 120, the difference in body weight versus placebo had narrowed from 12.4 percentage points to approximately 6 percentage points. [6]

SURMOUNT-4 showed a similar pattern with tirzepatide, suggesting this is a class effect rather than a semaglutide-specific finding. [9] Obesity is a chronic condition driven by persistent neuroendocrine dysregulation. Stopping the medication removes the pharmacological support for reduced appetite, and weight returns in most patients unless other metabolic or behavioral factors have changed substantially.

Patients planning to discontinue should discuss a supervised transition plan with their prescriber. Some clinicians step patients down to a lower maintenance dose (1.7 mg weekly) rather than abrupt cessation, though no published trial has evaluated whether gradual tapering reduces the rate of weight regain.

Comparing GLP-1 and Dual GLP-1/GIP Agents: A Clinical Decision Framework

Choosing among Wegovy, Ozempic, Zepbound, and Saxenda involves weighing efficacy targets, injection frequency, comorbidities, and insurance coverage.

| Drug | Active Ingredient | Dose | Injection Frequency | Mean Weight Loss | Primary FDA Indication | |---|---|---|---|---|---| | Wegovy | Semaglutide | 2.4 mg | Weekly | ~15% | Chronic weight management | | Ozempic | Semaglutide | Up to 2 mg | Weekly | ~6-10% | Type 2 diabetes | | Zepbound | Tirzepatide | Up to 15 mg | Weekly | ~21% | Chronic weight management | | Saxenda | Liraglutide | 3.0 mg | Daily | ~6-7% | Chronic weight management |

Patients with type 2 diabetes seeking both glycemic control and weight loss may find that Mounjaro (tirzepatide, the diabetes-labeled version of Zepbound) or Ozempic better align with their insurance coverage than the obesity-specific agents. SURMOUNT-2 (N=938) showed tirzepatide 15 mg produced 15.7% weight loss and a 2.4 percentage-point A1C reduction in adults with type 2 diabetes and obesity. [12]

Patients with established cardiovascular disease and BMI ≥27 now have a specific FDA-approved indication for Wegovy following SELECT, giving it a formulary argument that extends beyond simple weight reduction. [10]

For patients who have already achieved significant weight loss through an intensive lifestyle program and want to maintain it, SURMOUNT-3 (N=579) showed that adding tirzepatide to a prior lifestyle-intervention weight loss of at least 5% produced a further 18.4% reduction versus 2.5% with placebo over 72 weeks. [13] No equivalent study has been published for semaglutide 2.4 mg in a post-lifestyle-intervention maintenance design.

How to Get a Wegovy Prescription

Wegovy requires a prescription from a licensed clinician. Telemedicine platforms have significantly expanded access; a patient typically completes a medical history intake, a synchronous or asynchronous clinician visit, and, if appropriate, receives an electronic prescription sent to a specialty pharmacy.

The FDA requires documentation of qualifying BMI or BMI plus comorbidity before prescribing. Many prescribers also request a recent metabolic panel, lipid panel, thyroid function test, and fasting glucose or A1C to establish a baseline and screen for contraindications. [1][11]

Novo Nordisk's savings card for commercially insured patients brings the out-of-pocket cost to as low as $25 per month for eligible patients. Medicare Part D plans became permitted to cover anti-obesity medications under the Inflation Reduction Act framework beginning in 2026, expanding access for older adults.

Compounded semaglutide products were widely available during the 2022 to 2024 shortage period. The FDA removed semaglutide from its drug shortage list in early 2024, which means compounding pharmacies are no longer permitted to produce copies of Wegovy or Ozempic under federal law as of mid-2024. Patients using compounded versions should transition to FDA-approved products. [1]